NEW YORK (GenomeWeb) – Sophia Genetics announced today that its Hereditary Cancer Solution has received CE-IVD certification.

The genetic screen uses Integrated DNA Technologies' xGen Lockdown Probes to look at 27 genes relevant to breast, ovarian, and gastrointestinal hereditary cancers and includes specialized analytics developed by Sophia. The CE Mark applies to the combination of target capture technology and analytics, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.